Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-868
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
CT-868 is a once-daily subcutaneous injectable, dual glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist developed as an adjunct to insulin for the treatment of type 1 diabetes in people with overweight or obesity. It is also being investigated for type 2 diabetes. CT-868 is a peptide-small molecule hybrid designed to be potent on both GLP-1 and GIP receptors with no β-arrestin recruitment, resulting in fully biased signaling that minimizes receptor internalization and desensitization. This mechanism aims to provide improved glycemic control and weight loss while optimizing tolerability at the GLP-1 receptor. The drug was originally developed by Carmot Therapeutics, which has since been acquired by Roche[1][3][5][6].
- Other names
- GLP-1/GIP receptor agonist - Carmot Therapeutics
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on CT-868.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-868.